Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic
Abstract Aims Wild type transthyretin amyloidosis (ATTRwt) has gained interest during recent years due to better diagnostic tools and the emergence of treatment options. Little is known about the prevalence of the disease. We aimed to investigate the prevalence in a heart failure population with myo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-02-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13110 |
| _version_ | 1818879802297286656 |
|---|---|
| author | Krister Lindmark Björn Pilebro Torbjörn Sundström Per Lindqvist |
| author_facet | Krister Lindmark Björn Pilebro Torbjörn Sundström Per Lindqvist |
| author_sort | Krister Lindmark |
| collection | DOAJ |
| description | Abstract Aims Wild type transthyretin amyloidosis (ATTRwt) has gained interest during recent years due to better diagnostic tools and the emergence of treatment options. Little is known about the prevalence of the disease. We aimed to investigate the prevalence in a heart failure population with myocardial hypertrophy. Methods and results All patients with an ICD code of heart failure living within the catchment area of Umeå University hospital and intraventricular septum >14 mm were offered screening with 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scan and a clinical work up. Out of 2238 patients with heart failure, 174 patients were found to have a septum >14 mm. Ten patients were already diagnosed with hereditary ATTR cardiomyopathy, 12 patients had ATTRwt cardiomyopathy, 12 patients had known HCM, one patient had AL amyloidosis, and four patients had already undergone a negative DPD scan (DPD uptake grade 0 and 1) within the last 3 years. This left 134 patients who we tried to contact for screening, but 48 patients had either died or declined to participate. Out of 86 screened patients, 13 had a DPD uptake of grade 2 or 3 without other amyloid disease making the total number of patients with ATTRwt in this population 25. Conclusions Approximately 20% of investigated patients in a cohort with heart failure and increased myocardial wall thickness has ATTRwt. Calculated for the whole population of heart failure patients, the prevalence is just over 1.1%. Comparing this number to the total population would give an estimated prevalence of 1:6000. |
| first_indexed | 2024-12-19T14:35:52Z |
| format | Article |
| id | doaj.art-90716e29511f4d07ada9de8b3efede04 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-19T14:35:52Z |
| publishDate | 2021-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-90716e29511f4d07ada9de8b3efede042022-12-21T20:17:16ZengWileyESC Heart Failure2055-58222021-02-018174574910.1002/ehf2.13110Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinicKrister Lindmark0Björn Pilebro1Torbjörn Sundström2Per Lindqvist3Heart Centre, Department of Public Health and Clinical Medicine Umeå University Umeå SwedenHeart Centre, Department of Public Health and Clinical Medicine Umeå University Umeå SwedenDiagnostic Radiology, Department of Radiation Sciences Umeå University Umeå SwedenHeart Centre, Department of Surgery and Perioperative Sciences Umeå University Umeå SwedenAbstract Aims Wild type transthyretin amyloidosis (ATTRwt) has gained interest during recent years due to better diagnostic tools and the emergence of treatment options. Little is known about the prevalence of the disease. We aimed to investigate the prevalence in a heart failure population with myocardial hypertrophy. Methods and results All patients with an ICD code of heart failure living within the catchment area of Umeå University hospital and intraventricular septum >14 mm were offered screening with 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scan and a clinical work up. Out of 2238 patients with heart failure, 174 patients were found to have a septum >14 mm. Ten patients were already diagnosed with hereditary ATTR cardiomyopathy, 12 patients had ATTRwt cardiomyopathy, 12 patients had known HCM, one patient had AL amyloidosis, and four patients had already undergone a negative DPD scan (DPD uptake grade 0 and 1) within the last 3 years. This left 134 patients who we tried to contact for screening, but 48 patients had either died or declined to participate. Out of 86 screened patients, 13 had a DPD uptake of grade 2 or 3 without other amyloid disease making the total number of patients with ATTRwt in this population 25. Conclusions Approximately 20% of investigated patients in a cohort with heart failure and increased myocardial wall thickness has ATTRwt. Calculated for the whole population of heart failure patients, the prevalence is just over 1.1%. Comparing this number to the total population would give an estimated prevalence of 1:6000.https://doi.org/10.1002/ehf2.13110ATTRwtCardiac amyloidosisAmyloidosisHeart failureTransthyretin amyloidosis |
| spellingShingle | Krister Lindmark Björn Pilebro Torbjörn Sundström Per Lindqvist Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic ESC Heart Failure ATTRwt Cardiac amyloidosis Amyloidosis Heart failure Transthyretin amyloidosis |
| title | Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic |
| title_full | Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic |
| title_fullStr | Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic |
| title_full_unstemmed | Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic |
| title_short | Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic |
| title_sort | prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic |
| topic | ATTRwt Cardiac amyloidosis Amyloidosis Heart failure Transthyretin amyloidosis |
| url | https://doi.org/10.1002/ehf2.13110 |
| work_keys_str_mv | AT kristerlindmark prevalenceofwildtypetranstyrethincardiacamyloidosisinaheartfailureclinic AT bjornpilebro prevalenceofwildtypetranstyrethincardiacamyloidosisinaheartfailureclinic AT torbjornsundstrom prevalenceofwildtypetranstyrethincardiacamyloidosisinaheartfailureclinic AT perlindqvist prevalenceofwildtypetranstyrethincardiacamyloidosisinaheartfailureclinic |